ANDAs For Proteins Regulated As Drugs Could Lead To Lawsuits - Genzyme
Executive Summary
FDA could face legal challenges if it accepts abbreviated NDAs for products regulated as drugs that possess characteristics similar to biologics, Genzyme Senior VP-Government Relations Lisa Raines argued Oct. 3 at the Regulatory Affairs Professionals Society conference in Washington, D.C.